Diamedica Therapeutics Inc. (DMAC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Diamedica Therapeutics Inc. on January 5, 2026, reporting an event that occurred on December 19, 2025. The Company is incorporated in British Columbia and its common shares trade on The Nasdaq Stock Market LLC under the symbol "DMAC."
Key Financial Metrics
The filing details a specific capital raising event rather than periodic financial performance metrics.
- Gross Proceeds: $12.2 million
- Shares Sold: 1,501,000 common shares
- Purchase Price: $8.10 per share
- Transaction Type: Block transaction under an at-the-market offering program
- Buyer: A healthcare institution fund
The filing does not provide data on revenue, profit, operating cash flow, margins, total debt, or liquidity positions beyond the proceeds from this specific transaction.
Material Changes
The material change reported is the issuance of 1,501,000 shares, resulting in an increase in outstanding common stock and cash assets (gross proceeds of $12.2 million). No comparative period data is provided in this filing to assess changes in operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to future operations. It strictly reports the execution of the share sale. The text notes that the $12.2 million figure represents gross proceeds before deducting fees and other expenses payable by the Company.
Investor Verification Checklist
- Verify the net proceeds after deducting transaction fees and expenses.
- Confirm the updated total number of outstanding shares following this issuance.
- Review the remaining capacity under the Company's at-the-market offering program.
- Check for any subsequent filings regarding the use of these proceeds.